Strattera
Indicated to support cognitive function in attention deficit hyperactivity disorder, formulated to address executive dysfunction and alleviate impulsivity during daily activities.
- Categories
- Neurology · Nootropics
- Active ingredient
- Atomoxetine
- Supply
- Rx
- Route
- Oral use
- Form
- Capsule, hard
- Strengths
- 10 · 18 · 25 · 40mg
Strattera details
- Therapeutic class
- Selective Norepinephrine Reuptake Inhibitor
- Pharmacological class
- SNRI
- Minor side effects
- nausea; vomiting; decreased appetite; dry mouth
- Moderate side effects
- insomnia; tachycardia; palpitations; irritability
- Dosage forms
- Capsule, hard
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Eli Lilly
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store at room temperature in a dry place.
- Drug interactions
- MAO inhibitors; salbutamol; antihypertensives
- Age restrictions
- Not recommended for children under 6 years of age.
Contraindications
hypersensitivity to atomoxetine; narrow-angle glaucoma; severe cardiovascular disorders; concurrent use of monoamine oxidase inhibitors; phaeochromocytoma
Precautions and warnings
monitor blood pressure and heart rate; monitor for suicidal ideation in children; avoid use if pre-existing heart conditions present
Serious side effects
liver injury, requires immediate medical attention; arrhythmia, requires immediate medical attention; suicidal ideation, requires immediate medical attention
Patient summary
Indicated to support cognitive function in attention deficit hyperactivity disorder, formulated to address executive dysfunction and alleviate impulsivity during daily activities.
Mechanism of action
Atomoxetine acts as a selective inhibitor of the presynaptic norepinephrine transporter. By preventing the reuptake of norepinephrine, it increases the neurotransmitter's concentration in the synaptic cleft, particularly in the prefrontal cortex, thereby enhancing attention and impulse control.
Pregnancy and breastfeeding
Not recommended during pregnancy unless clearly necessary. Consult a physician regarding breastfeeding.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Strattera
Strattera contains atomoxetine, a medication used to treat Attention Deficit Hyperactivity Disorder. Produced by Eli Lilly, this treatment comes as a tablet available in 10, 18, 25, and 40mg strengths. It provides a standard approach for individuals seeking management for the symptoms associated with this condition.
Strattera availability in Asia
Strattera is registered across 14 markets including Taiwan, South Korea and Japan, with availability also in the UAE, Singapore and Hong Kong. Generic atomoxetine, much of it made in India, is far more affordable than the original brand, providing an accessible option for expats and those living in regions where local supply may be limited. This medication is best used under a doctor’s care.